The HELlenic Thoracic Society Initiative for CΟPD and CVD
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age35-99
SponsorHellenic Thoracic Society
About this trial
COPD is one of the most common respiratory diseases in Greece, and maybe more than half a million Greek citizens suffer both from COPD and CVD, however their characteristics and management remain unknown. HELICOPD is a national, multicenter, prospective, non-interventional study designed to contribute to better understanding and depicting the demographic and clinical characteristics of this population, the COPD- and CVD-related adverse events in a two-years period, their quality of life and the healthcare resources use. The study is initiated and coordinated by the Hellenic Thoracic Society.
Eligibility criteria
Qualifiers
To have been diagnosed with chronic obstructive pulmonary disease and at least one cardiovascular comorbidity (heart failure, atherosclerotic cardiovascular disease, atrial Fibrillation, severe valvular disease)
Adults aged >35 years at the time of inclusion in the study,
With signed informed consent for their participation in the study.
Disqualifiers
Without at least one cardiovascular comorbidity,
With history of lung cancer
With any other active malignancy and undergoing treatment (chemotherapy/radiotherapy/immunotherapy)
With any thoracic or abdominal surgery planned during study follow-up period
Trial design
Treatments tested in this trial
- Not listed
Trial groups
900 Participants
are grouped into 1 trial groupSponsors and collaborators
Source ClinicalTrials.gov